Frequently Asked Questions
The market is segmented based on , By Grade (Low Grade, High Grade and Other), Classification (Leiomyosarcoma of Soft Tissue, Leiomyosarcoma of Cutaneous Origin, Leiomyosarcoma of Vascular Origin, Leiomyosarcoma in the Immunocompromised Host and Leiomyosarcoma of Bone), Diagnosis (Blood Test, Computerized Tomography (CT) Scanning, Magnetic Resonance Imaging (MRI) and Ultrasound), Treatment (Surgery, Radiation Therapy and Chemotherapy), End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Leiomyosarcoma Treatment Market size was valued at USD 584.12 USD Million in 2022.
The Global Leiomyosarcoma Treatment Market is projected to grow at a CAGR of 4.3% during the forecast period of 2023 to 2030.
The major players operating in the market include GSK, F. Hoffmann, La Roche, Novartis, AstraZeneca, Pfizer, Bristol Myers Squibb, Sanofi, Amgen, Daiichi Sankyo, AB Sciences, Eisai, Genentech, Merck & Co..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
